High Growth Tech Stocks In Asia With Promising Potential

Jul 17, 2025
high-growth-tech-stocks-in-asia-with-promising-potential

Simply Wall St

4 min read

In This Article:

Amid a backdrop of muted reactions to new U.S. tariffs and mixed economic data, Asian markets have shown resilience, with the Chinese stock market experiencing gains due to hopes for further stimulus measures. In this environment, identifying high-growth tech stocks in Asia involves looking at companies that demonstrate strong innovation capabilities and adaptability to changing trade dynamics while maintaining robust financial health.

Name

Revenue Growth

Earnings Growth

Growth Rating

Suzhou TFC Optical Communication

30.19%

29.63%

★★★★★★

Shengyi Electronics

22.99%

35.16%

★★★★★★

Shanghai Huace Navigation Technology

24.51%

23.48%

★★★★★★

Fositek

29.16%

36.17%

★★★★★★

Range Intelligent Computing Technology Group

27.31%

28.63%

★★★★★★

eWeLLLtd

24.95%

24.40%

★★★★★★

Global Security Experts

20.56%

28.04%

★★★★★★

Marketingforce Management

26.39%

112.30%

★★★★★★

CARsgen Therapeutics Holdings

81.53%

96.08%

★★★★★★

JNTC

55.45%

94.52%

★★★★★★

Click here to see the full list of 474 stocks from our Asian High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, and internationally, with a market cap of HK$147.35 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to CN¥9.42 billion.

Innovent Biologics has recently made significant strides in addressing China’s growing obesity and diabetes epidemic. With the approval of mazdutide, a novel dual GCG/GLP-1 receptor agonist, Innovent is at the forefront of providing innovative solutions for chronic weight management. This drug not only aligns with national health priorities but also demonstrates substantial efficacy in reducing body weight and improving metabolic health, as evidenced by its pivotal GLORY-1 study results. Moreover, Innovent’s successful HKD 4.31 billion equity offering underscores robust market confidence in its strategic direction and R&D capabilities, positioning it well for future growth within Asia’s biopharmaceutical sector.

SEHK:1801 Earnings and Revenue Growth as at Jul 2025

SEHK:1801 Earnings and Revenue Growth as at Jul 2025

Simply Wall St Growth Rating: ★★★★★★

Overview: Marketingforce Management Ltd offers software as a service (SaaS) solutions in China and has a market capitalization of HK$13.25 billion.

Leave a comment